RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

Stock Information for RegeneRx Biopharmaceuticals

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About RegeneRx Biopharmaceuticals

RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
RegeneRx Receives Stockholder Approval for Reverse Stock Split
RegeneRx To Extend Consent Solicitation Vote
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259
RegeneRx Issues Letter To Stockholders
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.